Blue Goat CyberBlue Goat CyberSMMedical Device Cybersecurity
    Start here
    Services
    • Medical Device Cybersecurity Consulting
    • FDA Premarket Cybersecurity Package
    • Medical Device Penetration Testing Services
    • FDA Deficiency Response
    • FDA Postmarket Cybersecurity
    • Medical Device Threat Modeling
    • eSTAR Cybersecurity Documentation Support
    See all services
    Products

    Blue Goat products

    • GoatWatch logoGoatWatchSBOM risk management for medical devices
    About
    Resources

    Learn

    • Blog
    • Podcast
    • Webinars
    • Talks & workshops
    • Glossary
    • FAQs

    Playbooks & Tools

    • Guides
    • Playbooks (PDF)
    • Infographics
    • Interactive Tools

    Signals & Proof

    • Goat FeedNew
    • News
    • Medical Device Security News
    • The Goat's Weekly
    • Case Studies
    • Proof / Receipts
    All resources, topic hubs, & collections →
    ⌘K
    Book Strategy SessionHow to prepare →
    Blue Goat Cyber

    Full-service medical device cybersecurity. We protect patients by securing connected medical devices from design through postmarket.

    275+ FDA submissions supported, zero cybersecurity rejections · Mission: 1,000 by 2028

    SDVOSB · Service-Disabled Veteran-Owned Small Business

    We sponsor 10 community projects →

    Services

    • FDA Premarket Cybersecurity Package
    • FDA Deficiency Response
    • Medical Device Threat Modeling
    • Medical Device Penetration Testing Services
    • FDA Postmarket Cybersecurity
    • All services →
    Services
    • FDA Premarket Cybersecurity Package
    • FDA Deficiency Response
    • Medical Device Threat Modeling
    • Medical Device Penetration Testing Services
    • FDA Postmarket Cybersecurity
    • All services →

    Company

    • About
    • Core values
    • Manifesto
    • Leadership
    • Why Us
    • Partners
    • Careers
    • Press
    • Press kit
    • Contact
    • Company overviewPDF
    Company
    • About
    • Core values
    • Manifesto
    • Leadership
    • Why Us
    • Partners
    • Careers
    • Press
    • Press kit
    • Contact
    • Company overviewPDF

    Resources

    • Blog
    • Guides
    • Podcast
    • Case studies
    • Monthly Pulse newsletter
    • All resources →
    Resources
    • Blog
    • Guides
    • Podcast
    • Case studies
    • Monthly Pulse newsletter
    • All resources →

    Get in touch

    • info@bluegoatcyber.com
    • 844-939-GOAT
    • Book a strategy session →
    • 1776 N Scottsdale Rd, Unit 727
      Scottsdale, AZ 85257Serving clients worldwide

    Follow

    © 2026 Blue Goat Cyber. All rights reserved.

    • Privacy
    • Terms
    • Cookies
    • Sitemap
    • Accessibility
    • CVD

    MedTech Cybersecurity · Since 2022

    Part of every penetration test

    Week 1 test readiness review

    Before we test, we check that your threat model, hazard analysis, and eSTAR architecture diagram line up, so every finding traces from diagram to threat to patient harm.

    How it works

    In the first week of a medical device penetration test, we review your threat model, hazard analysis, security architecture views, and eSTAR software architecture diagram against the checklist below. You get a short review memo with each item rated, in three parts.

    Met

    Ready for testing and traceable.

    Partly met

    Testing can proceed; fix before you submit.

    Not met

    A traceability gap a reviewer is likely to question.

    Part A: Threat model

    Is the threat model complete enough to aim the test at the right places?

    IDWhat we checkWhy it matters for the test
    A1The system is modeled with data flows, data stores, processes, external entities, and trust boundaries.Without the full system, test targets are guesses.
    A2Every entry point in scope is represented, with protocols named on high-value flows.Each entry point becomes a test target.
    A3Threats are listed per element using STRIDE, each with a stable threat ID.Findings in the report trace back to these IDs.
    A4STRIDE sorts threats into types; it is not used to score them.Mixing the two hides which threats matter most.
    A5Risk is scored on exploitability, not likelihood or probability.The FDA expects exploitability for security risk.
    A6Each threat has a control strategy: eliminate, mitigate, accept, or transfer.Mitigated threats get tests that prove the control works.
    A7Assumptions and security context are stated, including the update path and system boundaries.Unstated assumptions become untested gaps.

    Part B: Hazard analysis

    Does each security threat connect to patient harm?

    IDWhat we checkWhy it matters for the test
    B1Cybersecurity-initiated hazards are included, especially the patient effects of losing confidentiality, integrity, or availability.Test findings are rated by patient harm, not CVSS alone.
    B2Severity is rated on the ISO 14971 scale, separately from security scoring.Severity and exploitability are two different questions.
    B3Threat IDs map to hazard IDs.This is the link a reviewer follows from finding to harm.

    Part C: eSTAR architecture diagram and security views

    Do the eSTAR software architecture diagram, the security architecture views, and the threat model describe the same system?

    IDWhat we checkWhy it matters for the test
    C1The security views start from the same system as the eSTAR software architecture diagram.Two different pictures of one device draw reviewer questions.
    C2Components use the same names in the diagram, views, threat model, and SBOM.Mismatched names break traceability.
    C3Every external interface in the diagram crosses a trust boundary in the views and appears in the threat model.Missing interfaces are missing test targets.
    C4The global system view shows which paths could reach many devices from one entry point.Multi-patient harm paths get their own tests.
    C5The updatability view matches the update path in the threat model.Update-path tests, such as unsigned or older firmware, come from here.
    C6The diagram, views, threat model, and SBOM all describe the same software version.The test must run on the version you submit.

    How Part C matches the eSTAR diagram

    The eSTAR asks for a software architecture diagram in the software section and security architecture views in the cybersecurity section. They should be two views of one system. Part C checks that rule before testing, because the test targets come from the interfaces and trust boundaries in those pictures. See FDA cybersecurity architecture views for the side-by-side comparison, and eSTAR software documents and cybersecurity for how the two sections stay consistent.

    Get ready before testing

    Try the free Threat Model Starter, read the cybersecurity hazard analysis guide, or book a threat model gap assessment for a deeper review.

    FAQ

    What is a test readiness review?
    It is the first-week check in a Blue Goat Cyber medical device penetration test. We review your threat model, hazard analysis, and architecture against a fixed list, mark each item met, partly met, or not met, and confirm the test can trace each finding back to a threat, a hazard, and a component.
    What if items are not met?
    Testing still goes ahead. The memo tells you what each gap means for traceability and what to fix before you submit. If the gaps are large, we can scope deeper rework separately at a fixed fee.
    Is it the same as a threat model gap assessment?
    No. The readiness review is a short check inside a penetration test, focused on whether the test can be aimed and traced. A gap assessment is a stand-alone, deeper review of your threat model and hazard analysis against FDA expectations, with a fixed fee after scoping.
    Does it cover the eSTAR software documents?
    Part C checks that the eSTAR software architecture diagram, the security architecture views, the threat model, and the SBOM describe the same system and version. It does not review the other software documents, which your team prepares.

    Ready to scope a test? Book a discovery call.